Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex with a general formula [{Ru(CO)(L-?2[N,S]?)(PiPr3)2}2(?—{CH?CH—C6H2—(iPr)2-2,6}2—N?N-4,4?)], its synthesis, and its use as an catalyst in inorganic processes.

Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.

Abstract: An ultraviolet radiation absorbing composition can be used as a light stabilizer for a shaped artificial polymer article, wherein the polymer is a synthetic polymer and/or a natural elastomer and wherein the ultraviolet radiation absorbing composition includes the compound of formula (I) wherein n and m are independently 0 to 20, and at least one of m and n being ?1; and X1, X2, X3, X4 and X5 are the same or different and are independently selected from H, C(O)R1 with R1 being C8-C24-alkyl, or a group of the general formula (II) wherein R2 is H or halogen.

Abstract: Methods and compositions are provided for treating endometriosis in an individual, and the pain associated with endometriosis. Aspects of the methods include administering to the individual an agent that promotes ALDH activity.

Abstract: A 4,4?-divinylazoarylene-bridged diruthenium complex bearing two Ru(CO)(2-mercaptoquinolato)(PiPr3)2 moieties, its synthesis, and its use as a catalyst.

Abstract: An 6-(3-hydroxyphenyl)-2-methoxy-4-(3-methylphenyl)nicotinonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.

Abstract: This invention pertains to the prevention and treatment of aging-associated disease. The invention relates to the use of benzodioxane inhibitors of leukotriene production through modulation of leukotriene A4 hydrolase (“LTA4H”) to treat and/or prevent conditions associated with aging such as cognitive disorders, motor disorders, and neuroinflammation.

Abstract: The present disclosure provides for compounds of Formula (I), its corresponding compounds of Formula (II) or salts thereof and their use as fluorogenic pH sensors.

Abstract: The present disclosure provides macrocyclic compounds inspired by the immunophilin ligand family of natural products FK506 and rapamycin. The generation of a Rapafucin library of macrocyles that contain FK506 and rapamycin binding domains should have great potential as new leads for developing drugs to be used for treating diseases.

Abstract: Provided are enantiomers of MDMA, such as R-MDMA and S-MDMA, and non-racemic mixtures thereof. In some embodiments, the provided mixtures comprise R-MDMA in enantiomeric excess. In other aspects, provided are methods of making such enantiomers and non-racemic mixtures, compositions thereof, and methods of using the same. In some aspects, features of the provided mixtures, compositions, and methods include improved pharmacokinetics, reduced toxicity, such as neurotoxicity, and a reduced potential for abuse. In some embodiments, improved pharmacokinetics include a reduced duration of action. In some embodiments, reduced toxicity and abuse potential result from distinct binding profiles compared to racemic MDMA, R-MDMA, or S-MDMA.

Abstract: An 2-(2-ethoxyethoxy)-6-phenyl-4,4?-bipyridine-3-carbonitrile compound, its synthesis, and its use as an antimicrobial agent.

Abstract: The invention relates to a high-performance sky blue thermally activated delayed fluorescent material, manufacturing method thereof, and application thereof, which solves the problems of the prior art. Through clever molecular design, a series of sky-blue thermally activated delayed fluorescent materials with less singlet-triplet energy level difference, high luminous efficiency, and fast-rate reverse intersystem crossing constant were synthesized, while fine-tuning of the structure and spectrum thereof were realized.

Abstract: A 1-cyclopropyl-6-fluoro-4-oxo-7-(4-((2-thioxobenzo[d]oxazol-3(2H)-yl)methyl)piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.

Abstract: This invention is related to the use of a volatile antimicrobial compound against pathogens. The volatile antimicrobial compounds provided include certain oxaborole compounds, for example benzoxaboroles. Delivery systems are provided to take advantage of the volatile nature of these antimicrobial compounds. The method and use disclosed can be combined with other volatile compounds.

Abstract: The present disclosure provides for a compound according to formula (I) or a pharmaceutically acceptable salt thereof as CaV1.22 activators for the treatment of schizophrenia, bipolar disorder, major depressive disorder, substance use disorder, ADHD, Phelan-McDermid Syndrome, autism spectrum disorder, multiple sclerosis, frontotemporal dementia, Alzheimer's disease, Brugada Syndrome, Short QT syndrome, or early repolarization syndrome.

Abstract: A method for treating a cancer involving one or more translocations generating an oncogenic fusion transcription factor that requires p300/CBP for activity in an animal, comprising administering a compound of formula (I): or a pharmaceutically acceptable salt thereof to the animal.

Abstract: The use of tocotrienols in medicine, veterinary or cosmetics, namely through the stabilization of tocotrienols, in particular in cosmetic formulations without hampering its functions in the skin is provided. In particular, the modification of tocotrienols with nicotinic acid results in the stabilization of the molecule and the penetration profile in human skin. The compounds and composition of are useful in medicine, veterinary or cosmetic industry namely in the prevention, therapy or treatment of skin diseases, skin disorders, or as a therapy or treatment of acne, seborrheic dermatitis or as an anti-aging agent.

Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.

Abstract: Compounds represented by general Formulae I to IV as described herein are disclosed. Further disclosed are composition utilizing the herein disclosed compounds and using the same for the treatment of glycogen storage disorders.